Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024)

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDiana SoteloMEMónica V. EstradaNDNatalia Duque

Discussion

Loading...

Member takes

Overview

Observational study shows progression-free survival and response rate among patients with DLBCL receiving polatuzumab-based regimens in Latin America, suggesting effective treatment in resource-constr

Key Points

  • Characterize clinical outcomes, treatment patterns, and response rates for DLBCL patients treated with polatuzumab-based regimens in a Latin American context.
  • Conducted a multicenter, retrospective observational study in adult DLBCL patients treated with polatuzumab-based regimens.
  • Data extracted from electronic medical records at three clinical centers from 2020 onward.
  • Descriptive statistics summarized patient characteristics and outcomes.
  • A total of 25 patients were included with a median age of 61 years and 65.4% male.
  • Response rates indicated successful treatment outcomes across multiple lines, with complete response rates of 100% in first-line therapy.
  • 1-year overall survival was estimated at 81.6%, with high-risk IPI correlating to worse survival outcomes.

Cite This Study

Sotelo et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e27chttps://doi.org/10.1182/blood-2025-7200
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025
  2. 2Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China2025
  3. 3Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  4. 4Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review2025
  5. 5Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)2025 · 2 citations